Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release : Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma

07/29/2021 | 01:15am EDT

Basel, Switzerland, July 29, 2021

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea's tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer.(1) Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity.

Dr. Marc Engelhardt, Chief Medical Officer, commented: "The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease."

Basilea is currently conducting a phase 1/2 study in patients with recurrent glioblastoma, using end-binding protein 1 (EB1) for patient selection.(2) In the previously reported phase 1 part of the study, long-lasting clinical benefit was observed in two patients with recurrent glioblastoma whose tumor tissues showed EB1-positive staining.(3) Interim results from the phase 2 part of the study are expected in the second half of 2021.

About lisavanbulin (BAL101553)

Basilea's oncology drug candidate lisavanbulin (BAL101553, the prodrug of BAL27862)(4) is currently being developed as a potential therapy for glioblastoma.(2, 5, 6) In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.(7, 8, 9) Lisavanbulin efficiently distributes to the brain, with anticancer activity in glioblastoma models.(10, 11) In preclinical studies, end-binding protein 1 (EB1) was identified as a potential response-predictive biomarker in glioblastoma models and strong EB1-positivity was shown in about 5% of tissue samples from glioblastoma patients.(12, 13) The strongest expression of EB1 in non-glioblastoma tumors was detected in tissue samples from medulloblastomas and neuroblastomas, which are cancers that occur predominantly in the pediatric population. EB1-positive staining was also found in tissue samples from metastatic melanoma (skin cancer). Other tumors expressing slightly lower levels of EB1 staining include non-small cell lung cancer, colorectal cancer and triple-negative breast cancer.(13) The active moiety BAL27862 binds to the colchicine site of tubulin, with distinct effects on microtubule organization,(14) resulting in the activation of the "spindle assembly checkpoint" which promotes tumor cell death.(15)

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com https://www.globenewswire.com/Tracker?data=zAOYgX5hqYNMMZvi0mtRhX7TTL3EoUa39ITYjPLKt1i0oZoMSujilrpvgxxu6Npmtrt2bUw4GlhAz4JikuzKcA== .


This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

  Peer Nils Schröder, PhD 
   Head of Corporate Communications & Investor Relations 
  Phone                                     +41 61 606 1102 
  E-mail        media_relations@basilea.com 

This press release can be downloaded from www.basilea.com.


   1. B. M. Alexander, T. F. Cloughesy. Adult Glioblastoma. Journal of Clinical 
      Oncology 2017 (35), 2402-2409 
   2. ClinicalTrials.gov identifier: NCT02490800; C. Tiu, S. Derby, N. Md. 
      Haris et al. The potential utility of end-binding protein 1 (EB1) as 
      response-predictive biomarker for lisavanbulin: A phase 2 study of 
      lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma. 
      Journal of Clinical Oncology 2021, 39 (15 supplement, TPS2068) 
   3. C. Tiu, A. Tzankov, R. Plummer et al. The potential utility of 
      end-binding protein 1 (EB1) as response-predictive biomarker for 
      lisavanbulin: Final results from a phase I study of lisavanbulin 
      (BAL101553) in adult patients with recurrent glioblastoma (GBM). Annals 
      of Oncology 2020 (31) supplement 4, S396-S408 
   4. J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An 
      optimized prodrug of the microtubule destabilizer BAL27862 with superior 
      antitumor activity. Cancer Research 2011, 71 (8 supplement), abstract 
   5. ClinicalTrials.gov identifier: NCT03250299 
   6. ClinicalTrials.gov identifier: NCT02895360 
   7. A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule 
      targeting agent BAL101553 in combination with radiotherapy in 
      treatment-refractory tumor models. Radiotherapy Oncology 2017 (124), 
   8. G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel 
      tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and 
      ovarian cancer variants selected for resistance to taxanes. Cancer 
      Research 2010, 70 (8 supplement), abstract 4412 
   9. F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of 
      BAL27862): A unique microtubule destabilizer active against drug 
      refractory breast cancers alone and in combination with trastuzumab. 
      Cancer Research 2014, 74 (19 supplement), abstract 831 
  10. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique 
      microtubule-targeted agent with a potential for the treatment of human 
      brain tumors. Molecular Cancer Therapeutics 2009, 8 (12 supplement), C233 
  11. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding 
      'tumor checkpoint controller' BAL101553 has anti-cancer activity alone 
      and in combination treatments across a panel of GBM patient-derived 
      xenografts. Cancer Research 2016, 76 (14 supplement), abstract 4781 
  12. R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel 
      tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent 
      migration and invasion and promotes differentiation of glioblastoma 
      stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749 
  13. M. Skowronska, C. Tiu, A. Tzankov et al. Expression of end-binding 
      protein 1 (EB1), a potential response-predictive biomarker for 
      lisavanbulin, in glioblastoma and various other solid tumor types. 
      Journal of Clinical Oncology 2021, 39 (15 supplement, 3118) 
  14. A. E. Prota, F. Danel, F. Bachmann et al. The novel 
      microtubule-destabilizing drug BAL27862 binds to the colchicine site of 
      tubulin with distinct effects on microtubule organization. Journal of 
      Molecular Biology 2014 (426), 1848-1860 
  15. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the 
      spindle assembly checkpoint is required for anticancer activity. Cancer 
      Research 2015, 75 (15 supplement), abstract 3789 


   -- Press release (PDF) 

(END) Dow Jones Newswires

July 29, 2021 01:15 ET (05:15 GMT)

09/17BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
09/17PRESS RELEASE : Basilea presents full safety and -2-
09/17Basilea presents full safety and efficacy data set on derazantinib in patients with FGF..
09/17PRESS RELEASE : Basilea presents full safety and efficacy data set on derazantinib in pati..
09/17Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib i..
08/17Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021
08/17PRESS RELEASE : Basilea reports strong financial -3-
08/17PRESS RELEASE : Basilea reports strong financial results for half-year 2021 with significa..
08/17PRESS RELEASE : Basilea reports strong financial -2-
08/17BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa..
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Sales 2021 136 M 148 M 148 M
Net income 2021 -21,5 M -23,3 M -23,3 M
Net Debt 2021 82,2 M 88,9 M 88,9 M
P/E ratio 2021 -21,5x
Yield 2021 -
Capitalization 524 M 567 M 567 M
EV / Sales 2021 4,44x
EV / Sales 2022 3,72x
Nbr of Employees 160
Free-Float 88,5%
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 44,40 CHF
Average target price 87,60 CHF
Spread / Average Target 97,3%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939